Bristol-Myers, Daiichi Sankyo to test combo therapy for breast, bladder cancers


Aug 28 (Reuters) - Bristol-Myers Squibb Co and Daiichi Sankyo said they would collaborate on a clinical trial to evaluate a combination of Bristol-Myers' immuno-oncology drug, Opdivo, with the Japanese company's experimental drug in patients with breast and bladder cancers.

The companies said the study in patients with HER2-expressing advanced breast and bladder cancer is expected to begin enrollment in the first quarter of 2018. (Reporting by Manas Mishra in Bengaluru; Editing by Anil D'Silva)